

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

Applicant: Shu-Ping Yang et al.

Title: ANTI-CHRONDROSARCOMA COMPOUNDS

Docket No.: 1443.064US1

Filed: June 20, 2003

Examiner: Maury A. Audet



Serial No.: 10/601,059

Due Date: January 21, 2006 (Saturday)

Group Art Unit: 1654

**MS Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

☒ Return postcard.

☒ Response to Restriction Requirement (13 pgs.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

*Robin A. Chadwick*

By: \_\_\_\_\_

Atty: Robin A. Chadwick

Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23rd day of January, 2006 (Monday).

CANDIS BUENDING

Name

*Candis Buending*

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)



S/N 10/153,185

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Shu-Ping Yang et al.	Examiner: Maury Audet
Serial No.:	10/601,059	Group Art Unit: 1654
Filed:	June 20, 2003	Docket: 1443.064US1
Title:	ANTI-CHONDROSARCOMA COMPOUNDS	

---

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Applicants have reviewed the Restriction Requirement mailed December 21, 2005 and elects, with traverse, the claims of Group II (claims 18-33), and peptide amino acid sequence SEQ ID NO:11 for prosecution at this time. As further described below, Applicants further request that the Examiner reconsider the species election and examine three peptide species with SEQ ID NO:11-13, because these peptides share significant sequence identity.